This is a randomized, multi-center phase II study of ginseng in colorectal cancer patients
treated with regorafenib to determine if ginseng will reduce fatigue in this patient
population and improve adherence to regorafenib. Ninety (90) subjects will be enrolled and
randomized using a 2:1 allocation, with 60 subjects enrolled in the regorafenib + ginseng
group and 30 enrolled in the regorafenib + no ginseng group.
Phase:
Phase 2
Details
Lead Sponsor:
Hoosier Cancer Research Network Rodwige J. Desnoyers